INSULIN ASPART Pharmacologic Class Indexing
- Class set ID
- ca9b5cf0-87e7-42b1-98f4-560896fffedf
- Version
- 5
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use NOVOLOG MIX 70/30 safely and effectively. See full prescribing information for NOVOLOG MIX 70/30. NOVOLOG ® MIX 70/30 (insulin aspart protamine and insulin aspart) injectable suspension, for subcutaneous use Initial U.S. Approval: 2001 | REMEDYREPACK INC. | 20260518 | 14 |
| These highlights do not include all the information needed to use INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 safely and effectively. See full prescribing information for INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30. INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 injectable suspension, for subcutaneous use Initial U.S. Approval: 2001 This product is NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart). | REMEDYREPACK INC. | 20260407 | 9 |
| These highlights do not include all the information needed to use NOVOLOG MIX 70/30 safely and effectively. See full prescribing information for NOVOLOG MIX 70/30. NOVOLOG ® MIX 70/30 (insulin aspart protamine and insulin aspart) injectable suspension, for subcutaneous use Initial U.S. Approval: 2001 | A-S Medication Solutions | 20260129 | 32 |
| These highlights do not include all the information needed to use INSULIN ASPART safely and effectively. See full prescribing information for INSULIN ASPART. INSULIN ASPART injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 This product is NovoLog (insulin aspart). | REMEDYREPACK INC. | 20260114 | 5 |
| These highlights do not include all the information needed to use MERILOG safely and effectively. See full prescribing information for MERILOG™. MERILOG (insulin aspart-szjj) injection, for subcutaneous use. Initial U.S. Approval: 2025 MERILOG™ (insulin aspart-szjj) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differe | Sanofi-Aventis U.S. LLC | Sanofi-Aventis Deutschland GmbH | 20251007 | 8 |
| These highlights do not include all the information needed to use KIRSTY safely and effectively. See full prescribing information for KIRSTY . KIRSTY ™ (insulin aspart-xjhz) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2025 KIRSTY™ (insulin aspart-xjhz) is biosimilar* to NOVOLOG (insulin aspart) | Biocon Biologics Inc. | BIOCON SDN.BHD. | 20250820 | 4 |
| These highlights do not include all the information needed to use INSULIN ASPART safely and effectively. See full prescribing information for INSULIN ASPART. INSULIN ASPART injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 This product is NovoLog (insulin aspart). | A-S Medication Solutions | 20240911 | 9 |
| These highlights do not include all the information needed to use INSULIN ASPART safely and effectively. See full prescribing information for INSULIN ASPART. INSULIN ASPART injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 This product is NovoLog (insulin aspart). | A-S Medication Solutions | 20240314 | 8 |
| These highlights do not include all the information needed to use INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 safely and effectively. See full prescribing information for INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30. INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 injectable suspension, for subcutaneous use Initial U.S. Approval: 2001 This product is NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart). | A-S Medication Solutions | 20240222 | 10 |
| These highlights do not include all the information needed to use NOVOLOG MIX 70/30 safely and effectively. See full prescribing information for NOVOLOG MIX 70/30. NOVOLOG ® MIX 70/30 (insulin aspart protamine and insulin aspart) injectable suspension, for subcutaneous use Initial U.S. Approval: 2001 | A-S Medication Solutions | 20240124 | 6 |
| These highlights do not include all the information needed to use NOVOLOG safely and effectively. See full prescribing information for NOVOLOG. NOVOLOG ® (insulin aspart) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 | A-S Medication Solutions | 20231215 | 6 |
| These highlights do not include all the information needed to use NOVOLOG safely and effectively. See full prescribing information for NOVOLOG. NOVOLOG ® (insulin aspart) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 | A-S Medication Solutions | 20231209 | 28 |
| These highlights do not include all the information needed to use FIASP safely and effectively. See full prescribing information for FIASP. FIASP ® (insulin aspart) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 | Novo Nordisk | 20230621 | 18 |
| These highlights do not include all the information needed to use INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 safely and effectively. See full prescribing information for INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30. INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 injectable suspension, for subcutaneous use Initial U.S. Approval: 2001 This product is NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart). | Novo Nordisk Pharma, Inc. | 20230228 | 7 |
| These highlights do not include all the information needed to use INSULIN ASPART safely and effectively. See full prescribing information for INSULIN ASPART. INSULIN ASPART injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 This product is NovoLog (insulin aspart). | Novo Nordisk Pharma, Inc. | 20230228 | 5 |
| These highlights do not include all the information needed to use NOVOLOG MIX 70/30 safely and effectively. See full prescribing information for NOVOLOG MIX 70/30. NOVOLOG ® MIX 70/30 (insulin aspart protamine and insulin aspart) injectable suspension, for subcutaneous use Initial U.S. Approval: 2001 | Novo Nordisk | 20230228 | 24 |
| These highlights do not include all the information needed to use NOVOLOG safely and effectively. See full prescribing information for NOVOLOG. NOVOLOG ® (insulin aspart) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2000 | Novo Nordisk | 20230228 | 34 |
| These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000 ® | TYA Pharmaceuticals | 20140425 | 2 |
| These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog. NovoLog ® (insulin aspart [rDNA origin] injection) solution for subcutaneous use Initial U.S. Approval: 2000 | Dispensing Solutions, Inc. | PSS World Medical, Inc. | 20130723 | 1 |
| These highlights do not include all the information needed to use NovoLog Mix 70/30 safely and effectively. See full prescribing information for NovoLog Mix 70/30. NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Suspension for subcutaneous injection Initial U.S. Approval: 2001 | Physicians Total Care, Inc. | 20101108 | 2 |